XHE - ETF AI Analysis
Top Page
SPDR S&P Health Care Equipment ETF (XHE)
Rating:63Neutral
Price Target:―
Positive Factors
Strong Performers Among Top Holdings
Several of the largest positions, such as DENTSPLY SIRONA, Glaukos, Butterfly Network, Enovis, and Conmed, have shown strong or steady performance, helping support the fund’s returns.
Focused Exposure to Health Care Equipment
The ETF is heavily focused on the health care sector, giving investors targeted access to medical equipment and related companies rather than a broad, mixed portfolio.
Moderate Expense Ratio
The fund’s expense ratio is moderate for a specialized sector ETF, so fees are not excessively high compared with many niche funds.
Negative Factors
Recent Weak Overall Performance
The ETF’s year-to-date performance has been weak, which means investors recently would have seen declines despite some strong individual holdings.
Several Lagging Top Holdings
A number of the largest positions, including Atricure, Inspire Medical Systems, Artivion, QuidelOrtho, and Omnicell, have been lagging, which can drag down the fund’s overall results.
High Concentration in U.S. Health Care
Almost all of the ETF’s holdings are U.S. health care companies, so investors face higher risk if this single country or sector runs into trouble.
XHE vs. SPDR S&P 500 ETF (SPY)
AUM175.99M
RegionNorth America
Expense Ratio0.35%
Beta0.81
IssuerSPDR
Inception DateJan 26, 2011
Dividend Yield0.1%
Asset ClassEquity
Index TrackedS&P Healthcare Equipment Select Industry
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume36,041
30 Day Avg. Volume30,053
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
111.45Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering67
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XHE Summary
The SPDR S&P Health Care Equipment ETF (XHE) is a fund that follows the S&P Health Care Equipment Select Industry Index, focusing on U.S. companies that make medical devices and supplies used in hospitals and clinics. It holds a mix of specialized health care firms such as DENTSPLY SIRONA and Glaukos, giving investors a simple way to invest in the growth of medical technology and an aging population that needs more care. However, because it is concentrated in health care equipment stocks, its price can go up or down sharply if this niche sector falls out of favor.
How much will it cost me?The SPDR S&P Health Care Equipment ETF (XHE) has an expense ratio of 0.35%, meaning you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is a sector-focused fund, which often requires more active management compared to broad-market index funds. However, it provides targeted exposure to the innovative health care equipment industry.
What would affect this ETF?The SPDR S&P Health Care Equipment ETF (XHE) could benefit from increased demand for innovative medical technologies and devices, driven by aging populations and advancements in health care. However, it may face challenges from regulatory changes, rising interest rates that impact growth-focused companies, or economic slowdowns that reduce health care spending. Its U.S.-focused portfolio and reliance on the health care equipment sector make it sensitive to domestic policy shifts and sector-specific trends.
XHE Top 10 Holdings
XHE is a pure play on U.S. health care equipment, and a handful of mid-cap names are steering the ship. Glaukos and NovoCure have been rising, giving the fund a lift as investors warm to their growth stories. Butterfly Network has surged over the year but its recent slide shows the ride can be bumpy. On the other side, QuidelOrtho, Artivion, and Inspire Medical Systems are lagging, acting like sandbags on performance. With no Big Tech or global diversification, this ETF lives and dies by specialized medical device momentum.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Butterfly Network | 2.47% | $4.24M | $2.40B | 613.24% | 59 Neutral | |
| Atricure | 2.27% | $3.90M | $2.11B | 17.31% | 71 Outperform | |
| Glaukos | 2.22% | $3.81M | $10.62B | 108.48% | 61 Neutral | |
| Inspire Medical Systems | 2.14% | $3.69M | $1.74B | -25.00% | 73 Outperform | |
| Tandem Diabetes Care | 2.08% | $3.57M | $1.56B | 125.51% | 61 Neutral | |
| Integer Holdings | 2.07% | $3.55M | $4.26B | 18.67% | 65 Neutral | |
| Baxter International | 2.04% | $3.51M | $14.24B | 18.41% | 45 Neutral | |
| Conmed | 2.04% | $3.50M | $1.47B | -5.75% | 67 Neutral | |
| Ufp Technologies | 2.04% | $3.50M | $2.43B | 52.18% | 75 Outperform | |
| Merit Medical Systems | 2.00% | $3.44M | $5.32B | 6.79% | 68 Neutral |
XHE Technical Analysis
Positive
―
Price Trends
86.62
Positive
83.37
Positive
84.68
Positive
Market Momentum
2.44
Negative
67.36
Neutral
93.79
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XHE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 90.34, equal to the 50-day MA of 86.62, and equal to the 200-day MA of 84.68, indicating a bullish trend. The MACD of 2.44 indicates Negative momentum. The RSI at 67.36 is Neutral, neither overbought nor oversold. The STOCH value of 93.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XHE.
XHE Peer Comparison
Comparison Results
Performance Comparison
XHE
SPDR S&P Health Care Equipment ETF
95.26
14.82
18.42%
FTXH
First Trust Nasdaq Pharmaceuticals ETF
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
XPH
SPDR S&P Pharmaceuticals ETF
―
―
―
PJP
Invesco Dynamic Pharmaceuticals ETF
―
―
―
PINK
Simplify Health Care ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents